The Manufacturers Life Insurance Company purchased a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the 2nd quarter, HoldingsChannel reports. The fund purchased 69,047 shares of the exchange traded fund’s stock, valued at approximately $10,927,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in XBI. Angeles Wealth Management LLC purchased a new position in SPDR S&P Biotech ETF during the second quarter worth about $28,000. Axiom Investment Management LLC purchased a new stake in shares of SPDR S&P Biotech ETF in the 1st quarter valued at about $26,000. Financial Life Planners purchased a new stake in shares of SPDR S&P Biotech ETF in the 1st quarter valued at about $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of SPDR S&P Biotech ETF in the 4th quarter valued at about $27,000. Finally, Morling Financial Advisors LLC bought a new stake in shares of SPDR S&P Biotech ETF during the 2nd quarter valued at about $36,000.
SPDR S&P Biotech ETF Trading Down 0.4%
Shares of NYSEARCA XBI opened at $156.20 on Friday. SPDR S&P Biotech ETF has a 12 month low of $92.64 and a 12 month high of $169.89. The firm has a market capitalization of $10.20 billion, a price-to-earnings ratio of 11.47 and a beta of 0.84. The business has a 50-day moving average of $158.26 and a 200-day moving average of $141.72.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Featured Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
